MANNKIND CORP Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31)
MANNKIND CORP (MNKD) reported Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) of -$48.00 thousand for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-10.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax · last filed 2012-05-10
- MANNKIND CORP other comprehensive income (loss), reclassification adjustment for sale of securities included in net income, net of tax (deprecated 2012-01-31) for the quarter ending 2012-03-31 was -$48.00K.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) 3 month | Other Comprehensive Income (Loss), Reclassification Adjustment for Sale of Securities Included in Net Income, Net of Tax (Deprecated 2012-01-31) 253 month |
|---|---|---|
| 2012-03-31 | -$48.00K 10-Q · filed 2012-05-10 | -$48.00K 10-Q · filed 2012-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |